Back to Search
MARIO EISENBERGER, M.D.
M.D.
Medical Oncology Physician
NPI: 1699722850Individual
Specialties, Licenses & Credentials
Research & Publications (20)
The role of cytotoxic chemotherapy in prostate cancer. A critical reevaluation 20 years later.
PMID 16922258·Oncology (Williston Park)·2006
6-review
Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action.
PMID 14751361·Urology·2004
3-trial
Therapeutic considerations for patients with high-risk, nonmetastatic, prostate cancer.
PMID 12198634·Semin Urol Oncol·2002
6-review
Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
PMID 18957947·Nat Clin Pract Oncol·2009
8-other
Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.
PMID 19125417·Prostate·2009
5-case
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.
PMID 19363497·Nat Med·2009
7-preclinical
LHRH antagonists vs LHRH agonists: which is more beneficial in prostate cancer therapy?
PMID 19626831·Oncology (Williston Park)·2009
8-other
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.
PMID 18574490·Prostate Cancer Prostatic Dis·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Request Appointment
This provider isn't set up for online booking yet. Once you submit, we'll reach out to their office to arrange secure delivery of your request.
Contact & Hours
- Address
- 600 N WOLFE ST
BALTIMORE, MD 21287 - Phone
- (410) 955-8964
Quick Facts
- NPI
- 1699722850
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile